Dipeptidyl Peptidase IV (DPP IV) Inhibitors Market Size, Share, and Industry Analysis, By Drug (Saxagliptin, Linagliptin, Empagliflozin, Sitagliptin, Alogliptin, and Others), By Type (Branded and Generic), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2026-2034

Last Updated: March 16, 2026 | Format: PDF | Report ID: FBI114750

Dipeptidyl Peptidase IV (DPP IV) Inhibitors Market Size & Future Outlook

The global dipeptidyl peptidase IV (DPP IV) inhibitors market size was valued at USD 12.38 billion in 2025. The market is projected to grow from USD 12.95 billion in 2026 to USD 18.65 billion by 2034, exhibiting a CAGR of 4.66% during the forecast period.

The global dipeptidyl peptidase IV (DPP IV) inhibitors market growth is driven by the rise in the prevalence of type 2 diabetes. Additionally, the growing aging population also drives market growth as the aging population is more prone to chronic diseases, such as type 2 diabetes. The dipeptidyl peptidase IV (DPP IV) inhibitors are a class of medications used to control type 2 diabetes by increasing the level of incretin hormones. Uncontrolled type 2 diabetes mellitus leads to a significant rise in the risk of coronary disease, heart failure, stroke, etc.

For instance, according to the data published by the American Diabetes Association in 2021, more than 16.5 million diagnosed and undiagnosed seniors (65 or more age) are suffering from diabetes. From this, more than 90% of patients have type 2 diabetes; thus, the rise in prevalence increases the market growth during the forecast period.

Dipeptidyl Peptidase IV (DPP IV) Inhibitors Market Driver

Increasing Prevalence of Type 2 Diabetes Mellitus Boosts Market Growth

The rise in the prevalence of type 2 diabetes mellitus globally has significantly driven the growth of the dipeptidyl peptidase IV (DPP IV) inhibitors market. Additionally, the rise in demand for effective oral antidiabetic medications also increases the market growth.

For instance, according to the data published by the Centers for Disease Control and Prevention (CDC) in May 2024, more than 38 million American population is suffering from diabetes, and 90% of them have type 2 diabetes. This high prevalence increases the adoption of DPP-IV inhibitor products and drives market growth.

The Rates of Diagnosed Diabetes in Adults by Race/Ethnic (in Percentage), By America, 2021

According to the data published by the American Diabetes Association in 2021, the projected data shows that American Indians have a higher rate of diagnosed diabetes in adults by race/ethnicity.

Dipeptidyl Peptidase IV (DPP IV) Inhibitors Market Restraint

Safety Concerns May Limit Market Growth

A few dipeptidyl peptidase IV (DPP IV) inhibitors have some side effects, such as pancreatitis and joint pain. These side effects raise a concern about the drug's safety profile, and if the drug has adverse reactions, then it gets banned globally or in region, leading to lower market growth.

Additionally, the launch of new medications, such as GLP-1 receptor agonists, which have low side effects and similar benefits as DPP-IV inhibitors, also limits the market growth.

For instance, in June 2023, Boehringer Ingelheim International GmbH & Co. discontinued TRADJENTA (linagliptin) due to its increased risk of hypoglycemia. These types of side effects reduce the product adoption rate and are expected to lower the market growth during the forecast period.

Dipeptidyl Peptidase IV (DPP IV) Inhibitors Market Opportunity

High Patient Adherence May Boost Market Growth in the Future

Dipeptidyl Peptidase IV (DPP IV) Inhibitors are taken orally, which increases the adherence of patients toward medications for a longer period and rises the growth of the market during the forecast years. Additionally, technological advancements such as AI and machine learning play an important role in identifying novel inhibitors; these technological advancements boost the growth of the market in the future. Moreover, new DPP-IV product launches also support market growth.

For instance, according to the data published on Frontiers in Pharmacology in January 2022, modern drugs such as DPP-IV, SGLT2, and GLP-1 are becoming popular in the pharmaceutical market. Using these drugs in combination with insulin therapy has gained attraction during the last decade, such as SGLT2 inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors. These types of new combinations raise the adoption of DPP-IV products and boost market growth.

Key Insights

The report covers the following key insights:

Prevalence of Type 2 Diabetes, By Key Countries, 2024
Pipeline Analysis, By Key Players
New Product Launches/ Approvals, By Key Players
Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
Impact of COVID-19 on the Market

Segmentation

By Drug	By Type	By Distribution Channel	By Region
Saxagliptin Linagliptin Sitagliptin Alogliptin Others	Branded Generic	Hospital Pharmacy Retail Pharmacy Online Pharmacy	North America (U.S. and Canada) Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Analysis by Drug

By drug, the market is divided into saxagliptin, linagliptin, empagliflozin, sitagliptin, alogliptin, and others.

The sitagliptin segment accounted for a significant revenue in the market. This drug is widely used to manage type 2 diabetes mellitus. Sitagliptin is efficient in reducing HbA1c and glucose levels, a well-tolerated, leading to a rise in the growth of the segment during the forecast period. Additionally, it has a neutral effect on body weight, which raises its adoption rate and supports market growth. Moreover, the government's support in accordance with controlling the price of DPP-IV inhibitors also increases market growth.

For instance, according to the data published by The Economic Times in February 2023, the National Pharmaceutical Pricing Authority fixed the retail price for 74 drugs, which include tablets of Dapagliflozin, Sitagliptin, and Metformin Hydrochloride (extended-release tablets) at INR 27.75 (USD 0.32). This government initiative raises the accessibility of DPP-IV inhibitor tablets and helps to increase market growth.

Analysis by Type

By type, the market is divided into branded and generic.

The market is segmented into branded and generic. The branded segment is expected to grow significantly during the forecast period. The growth of the segment is augmented by the strong brand recognition and robust efforts for marketing by the key players. Additionally, the key market players continuously develop new DPP IV drugs by supporting clinical trials, leading to an increase in market growth.

For instance, according to the data published by Frontiers in Endocrinology in June 2019, sitagliptin is the first dipeptidyl peptidase (DPP IV) inhibitor to enter into market. Due to early approval, sitagliptin is able to gain strong brand recognition, leading to boost the growth of the branded segment during the forecast period.

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy.

The market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacy held a significant share of the market in 2024. The significant share of the segment is due to the DPP-IV inhibitors being used in combination with other treatments to treat type 2 diabetes. Additionally, DPP-IV inhibitors are often prescribed in hospitals only, which leads to driving the growth of the segment during the forecast period.

For instance, according to the data published by the American Diabetic Association in December 2023, the hospital readmission rate for diabetic patients is 14% to 20%, which is approximately twice that of people without diabetes. This rise in readmission rate in hospitals increases the rate of distribution and supports market growth.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization to gain extensive market insights.

North America is expected to lead the global dipeptidyl peptidase (DPP IV) inhibitors market throughout the forecast period. This dominance can be attributed to several key factors, including a high prevalence of type 2 diabetes mellitus and advanced healthcare facilities, leading to early diagnosis and treatment. Additionally, the presence of key market players also boosts the growth of the market in this region.

For instance, in October 2023, Zydus Lifesciences Limited received approval from the U.S. Food and Drug Administration for the New Drug Application (NDA) of ZITUVIO. These new product launches and approvals help to increase the market growth in the future.

Europe has a considerable share of the global dipeptidyl peptidase (DPP IV) inhibitors market. The growth of the region is due to the rising prevalence of type 2 diabetes mellitus. Additionally, the presence of developed research institutes promotes innovation, leading to enhanced market growth in this region.

For instance, according to the data published by StatPearls in May 2023, vildagliptin, a DPP-IV inhibitor, is approved by the European Medicines Agency (EMA), but U.S. Food and Drug Administration does not approve it. This type of favorable regulatory landscape supports the market growth in this region.

The Asia Pacific region is experiencing rapid growth in the dipeptidyl peptidase (DPP IV) inhibitors market, driven by rising research & development activities with an increase in type 2 diabetes incidence rate.

Key Players Covered

The global dipeptidyl peptidase IV (DPP IV) inhibitors market is partially consolidated with a few key players. The report includes the profiles of the following key players:

AstraZeneca (U.K.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim International GmbH & Co. (Germany)
Eli Lilly and Company (U.S.)
Merck & Co., Inc. (U.S.)
Takeda Pharmaceutical Company Limited. (Japan)
Novartis AG (Switzerland)

Key Industry Developments

In July 2022, Glenmark Pharmaceuticals Limited launched sitagliptin and its Fixed Dose Combinations (FDCs) at an affordable price to treat type 2 diabetes in adults. They introduced 8 different combinations of sitagliptin-based drugs.
In June 2019, Boehringer Ingelheim and Eli Lilly and Company announced the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin, and metformin extended release (XR) accepted by the U.S. Food and Drug Administration (FDA) for the treatment of adults with type 2 diabetes.